Promotion of Access of Health Disparity Groups for Diabe

本研究核心旨在更好地了解少数民族人群中糖尿病危险因素和糖尿病管理之间的差距，这些人群患糖尿病、并发症和死亡率的风险明显更高。糖尿病核心的具体目标是：(1)促进健康差异群体参与糖尿病诊断和预防的研究和临床项目；(2)与社区团体合作，开展糖尿病研究

This research core is aimed at better understanding the gap between diabetes risk factors and diabetes management among racial and ethnic minority populations, which are at markedly higher risk of incurring diabetes, of complications, and of mortality. The specific aims of the Diabetes Core are: (1) to promote participation of health disparity groups in research and clinical programs in diagnosis and prevention of diabetes, and (2) to collaborate with community groups to develop innovative strategies to increase participation of racial and ethnic minorities in diabetes prevention and treatment programs. The focus of the Diabetes Research Core will be on enhancing the participation of racial and ethnic minorities in the conduct of ongoing diabetes studies and programs at the Naomi Berrie Diabetes Center at Columbia University. Working with the Community Core's Planning Council, the Diabetes Core will identify community partners to participate in discussions about the objectives of diabetes studies and to develop programs at their own organizations to enable more community residents to participate in either study design or implementation. Based on the work already underway with the schools, the core proposes to continue to prioritize work with young children and adolescents. The study coordinator will work through the Community Core to develop enhanced strategies for engaging schools, parents and adolescents in forums/ workshops about obesity, exercise and diabetes risk. Growing out of this participation, it is hoped not only that more schools will be interested in participating in ongoing studies, but that they will also work with the center to develop diabetes prevention activities. Through this participation, we seek to engage the Hispanic and African-American residents of northern Manhattan in three ongoing major studies: Type 2 diabetes in children and adolescents; the Diabetes Reduction Assessment with Ramipril and Rosiglitizone Medication (DREAM) trial; and the Prevention of Cardiovascular Disease in Diabetes (ACCORD) trial.